Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...
In 2024, the International Diabetes Federation published a position statement supporting the 1 h 75 g oral glucose tolerance test (OGTT) as an alternative to the conventional 2 h testing protocol and ...
These findings, alongside the linked systematic review and meta-analysis of antiviral treatment efficacy, supported the 2024 WHO guidelines expansion of treatment criteria to include individuals with ...
Revised 3.2. Measurement of TC, LDL-C, HDL-C, TG, and Non–HDL-C COR 2a: For adults with an LDL-C level <70 mg/dL (<1.8 mmol/L), measurement of direct LDL-C or modified LDL-C estimate is reasonable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results